Ferrocene derivative, preparation method therefor and use thereof
A ferrocene derivative of formula (I). In formula (I), Z is selected from O, NH and S; R 1 is selected from hydrogen, methyl and halogen; each R 2 is independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkoxy and nitro; and n is an integer from 0 to 5. The ferrocene derivative, a salt thereof, as well as a solvate thereof have anti-tumor activity, and can be used as candidate drugs or lead compounds for treating diseases such as tumors and cancer.
1. A ferrocene derivative of formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof:
wherein Z is selected from NH, O and S;
R 1 is selected from hydrogen, methyl, F and Cl;
R 2 is independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 haloalkyl and nitro; and
n is an integer from 0 to 5.
2. The ferrocene derivative of formula (I), the pharmaceutically acceptable salt thereof or the solvate thereof according to claim 1 , wherein
R 2 is independently selected from fluoro, chloro, bromo, methyl, ethyl, methoxy, trifluoromethyl, tert-butyl, cyano and nitro; and
n is 1, 2 or 3.
3. The ferrocene derivative of formula (I), the pharmaceutically acceptable salt thereof or the solvate thereof according to claim 1 , wherein the ferrocene derivative of formula (I) is selected from the following compounds:
4. A preparation method for the ferrocene derivative of formula (I) according to claim 1 , comprising the following steps:
(1) reacting ferrocenylethyne with a compound of formula A to give a ferrocene-containing intermediate of formula B,
wherein the compound of formula A is 3-(R 1 )-4-bromobenzoic acid with a structural formula of
and
the intermediate of formula B has a structural formula of
wherein R 1 is defined as in claim 1 ;
(2) reacting the intermediate of formula B with a compound of formula C to give the ferrocene derivative of formula (I),
wherein the compound of formula C has a structural formula of
and wherein R 2 and n are defined as in claim 1 , and Z′ represents NH 2 , OH or SH.
5. The preparation method according to claim 4 , wherein the compound of formula C is 3-substituted phenyl-5-hydroxymethyl-isoxazole (II), 3-substituted phenyl-5-mercaptomethyl-isoxazole, or 3-substituted phenyl-5-aminomethyl-isoxazole (III).
6. The preparation method according to claim 4 , wherein the reaction in step (2) is carried out in the presence of a condensing agent.
7. A pharmaceutical composition comprising the ferrocene derivative of formula (I), the pharmaceutically acceptable salt thereof or the solvate thereof according to claim 1 .
8. A pharmaceutical preparation comprising the ferrocene derivative of formula (I), the pharmaceutically acceptable salt thereof or the solvate thereof according to claim 1 , wherein the pharmaceutical preparation is a solid oral preparation, a liquid oral preparation or an injection.
9. A method for treating breast cancer, lung adenocarcinoma, or cervical cancer, comprising administering to a patient the ferrocene derivative of formula (I), the pharmaceutically acceptable salt thereof or the solvate thereof according to claim 1 .
10. A pharmaceutical composition comprising the ferrocene derivative of formula (I), the pharmaceutically acceptable salt thereof or the solvate thereof according to claim 2 .
11. A pharmaceutical composition comprising the ferrocene derivative of formula (I), the pharmaceutically acceptable salt thereof or the solvate thereof according to claim 3 .
12. A method for treating breast cancer, lung adenocarcinoma, or cervical cancer, comprising administering to a patient the ferrocene derivative of formula (I), the pharmaceutically acceptable salt thereof or the solvate thereof according to claim 2 .
13. A method for treating breast cancer, lung adenocarcinoma, or cervical cancer, comprising administering to a patient the ferrocene derivative of formula (I), the pharmaceutically acceptable salt thereof or the solvate thereof according to claim 3 .
14. The preparation method according to claim 4 , wherein step (1) is carried out in the presence of a palladium(II) compound, an organophosphorus compound and a copper(I) compound in a dried organic solvent in the presence of an alkaline deacid reagent; and the alkaline deacid reagent is selected from organic bases and inorganic bases.
15. The preparation method according to claim 14 , wherein the organic base is selected from triethylamine, tripropylamine, DMAP, DMF, N-methylmorpholine, and mixtures thereof, and the inorganic base is selected from potassium carbonate, sodium hydride, sodium carbonate, and mixtures thereof.
16. The preparation method according to claim 14 , wherein step (1) comprises the dispersing ferrocenylethyne and the compound of formula A in a mixture of the dried organic solvent and the alkaline deacid reagent, adding the palladium (II) compound, the organophosphorus compound and the copper (I) compound to the mixture while stirring to form a reaction system, stirring the reaction system, refluxing the reaction system, filtering the reaction system, and concentrating the filtrate to give the intermediate of formula B.
17. The preparation method according to claim 6 , wherein the condensing agent is selected from DCC, DMAP, NMM, HOBt, HATU, and mixtures thereof.
18. The preparation method according to claim 4 , wherein step (2) comprises adding the intermediate of formula B to a dried organic solvent, then adding a condensing agent for reaction, followed by adding the compound of formula C for reaction to give the ferrocene derivative of formula (I).